AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Altasciences Leads Research on Chemical Nerve Agent Therapeutic from Preclinical to Clinical Phase I

May 22, 2019

LAVAL, Québec--(BUSINESS WIRE)--May 22, 2019--

Altasciences announced today that they have been selected by Leidos Health to guide and support the development of RAP-103 peptide as a chemical nerve agent therapeutic on behalf of the Medical CBRN Defense Consortium and funded by the Defense Threat Reduction Agency (DTRA).

Altasciences will conduct the required Safety Testing, all IND-enabling studies (non-GLP and GLP), the necessary Phase I clinical trials, and associated bioanalytical analysis.

Altasciences’ preclinical and clinical teams are collaborating with Leidos Health on this important program. Together, we have developed a plan to move RAP-103 from preclinical, safely through early clinical trials. As a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development, we have the experience and team in place to complete this program successfully, on time and within budget,” explained Steve Mason, Vice President, Site Operations, at Altasciences.

For over 25 years, Altasciences has been helping sponsors move from one key milestone to the next with the goal of helping them make informed, faster and more complete early phase drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management — all of which can be tailored to specific sponsor requirements.

We have selected Altasciences for their ability to take us seamlessly from one key milestone to the next. The fact that we have one Altasciences program manager at our disposal through all phases is a true benefit and ensures seamless handoffs and communication along the way, ” stated Dr. Vinayaka Kotraiah, Preclinical Discovery Lead/Program Manager at Leidos Health.

About Altasciences

Altasciences  is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements. Altasciences… helping sponsors get better drugs to the people who need them, faster.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005422/en/

CONTACT: Julie-Ann Cabana

Altasciences

913 304-4505

jcabana@altasciences.com

KEYWORD: EUROPE NORTH AMERICA CANADA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL PROFESSIONAL SERVICES CONSULTING

SOURCE: Altasciences

Copyright Business Wire 2019.

PUB: 05/22/2019 08:04 AM/DISC: 05/22/2019 08:04 AM

http://www.businesswire.com/news/home/20190522005422/en

All contents © copyright 2019 The Associated Press. All rights reserved.